A Validation Study of the Neuro-cognitive Emotion Monitoring-Intervention (NEMO-I) Application in Adolescents
8 de julho de 2026 atualizado por: Seoul Women's University
This study aims to evaluate the validity and effectiveness of NEMO-I (Neuro-cognitive Emotion Monitoring-Intervention), a mobile application designed to help adolescents monitor and manage their cognitive and emotional functioning in everyday settings. NEMO-I delivers evidence-based psychological techniques-such as mindfulness, self-regulation training, and emotion monitoring-in a gamified format consisting of seven brief activities that users can complete at home in about 10 minutes each.
A total of 140 middle and high school students will participate. Participants will complete standardized neuropsychological and psychological assessments before and after the intervention period. During the 21-day intervention period, participants will use the NEMO-I application at home each day at their convenience (a minimum of 10 minutes per day is recommended). By comparing pre- and post-intervention assessment results, this study seeks to determine whether the application produces meaningful benefits for adolescent mental health and to establish its suitability as a digital mental health tool.
Visão geral do estudo
Status
Ainda não está recrutando
Intervenção / Tratamento
Tipo de estudo
Intervencional
Inscrição (Estimado)
140
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Contato de estudo
- Nome: Myeongjie Im, MA
- Número de telefone: +82-10-2588-0859
- E-mail: imj@swu.ac.kr
Locais de estudo
-
-
Seoul
-
Seoul, Seoul, Coréia do Sul, 01797
- Seoul Women's University
-
Contato:
- Myeongjie Im, MA
- Número de telefone: +82-10-2588-0859
- E-mail: imj@swu.ac.kr
-
Investigador principal:
- Hyunjoo Song, PhD
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
- Adulto
Aceita Voluntários Saudáveis
Sim
Descrição
Inclusion Criteria:
- Middle or high school students currently enrolled in school
- Using an Android-based smartphone
- Voluntary agreement to participate, with consent from a legal guardian
Exclusion Criteria:
- Borderline intellectual functioning or intellectual disability (IQ below 80)
- Visual or hearing impairment
- Prior diagnosis of intellectual, visual, or hearing impairment
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: NEMO-I Intervention Group
Participants in this single-arm study use the NEMO-I mobile application at home for 21 days, at their convenience each day (a minimum of 10 minutes per day is recommended).
Cognitive and emotional outcomes are assessed before and after the intervention period.
|
NEMO-I is a mobile application that delivers evidence-based psychological techniques in a gamified format.
It consists of seven brief activities-including facial expression imitation, singing, breathing and stretching with nature sounds, reading tips for everyday concerns, rhythm-based instrument play, room decoration, and mindfulness-each designed to be completed at home in about 10 minutes.
Participants use the application daily during the 21-day intervention period, at their convenience, with a recommended minimum of 10 minutes per day.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in depressive symptoms
Prazo: Baseline (pre-intervention) and after the 21-day intervention period
|
Depressive symptoms are measured using the Beck Depression Inventory-II (BDI-II), a 21-item self-report questionnaire.
Total scores range from 0 to 63, with higher scores indicating more severe depressive symptoms.
Change is assessed by comparing pre- and post-intervention scores.
|
Baseline (pre-intervention) and after the 21-day intervention period
|
|
Change in inhibitory control (Color-Word Stroop Test, CWST)
Prazo: Baseline(pre-intervention) and after the 21-day intervention period
|
Inhibitory control is assessed using the Color-Word Stroop Test (CWST), which measures the efficiency of the frontal-lobe inhibition process.
Performance is indexed by response time and error rate under the color-word interference condition.
Change is assessed by comparing pre- and post-intervention performance.
|
Baseline(pre-intervention) and after the 21-day intervention period
|
|
Change in anxiety symptoms
Prazo: Baseline(pre-intervention) and after the 21-day intervention period
|
Anxiety symptoms are measured using the Beck Anxiety Inventory (BAI), a 21-item self-report questionnaire assessing the severity of anxiety-related symptoms.
Higher scores indicate greater anxiety.
Change is assessed by comparing pre- and post-intervention scores.
|
Baseline(pre-intervention) and after the 21-day intervention period
|
|
Change in neuro-cognitive and emotional function (NEMO-A)
Prazo: Baseline (pre-intervention) and after the 21-day intervention period
|
Neuro-cognitive and emotional function is assessed using the NEMO-A (Neuro-cognitive Emotion Monitoring-Assessment) application, a tablet-based, game-format assessment consisting of five subtasks.
It measures domains including sustained attention, working memory, emotional sensitivity, emotion processing and recognition, audiovisual emotional integration, cognitive control, and executive function.
Performance is indexed by accuracy and response time, and change is assessed by comparing pre- and post-intervention performance.
|
Baseline (pre-intervention) and after the 21-day intervention period
|
|
Change in visual attention and processing speed (Children's Color Trails Test, CCTT)
Prazo: Baseline (pre-intervention) and after the 21-day intervention period
|
Visual attention, psychomotor speed, sequential processing, and divided/sustained visual attention are assessed using the Children's Color Trails Test (CCTT).
Performance is indexed by completion time (seconds).
Change is assessed by comparing pre- and post-intervention performance.
|
Baseline (pre-intervention) and after the 21-day intervention period
|
|
Change in set-shifting ability (Trail Making Test-B, TMT-B)
Prazo: Baseline (pre-intervention) and after the 21-day intervention period
|
Set-shifting ability and cognitive flexibility are assessed using the Trail Making Test-B (TMT-B), which requires alternating between numbers and letters in sequence.
Performance is indexed by completion time (seconds).
Change is assessed by comparing pre- and post-intervention performance.
|
Baseline (pre-intervention) and after the 21-day intervention period
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in subjective stress
Prazo: Baseline (pre-intervention) and after the 21-day intervention period
|
Subjective stress is measured using a Visual Analog Scale (VAS), on which participants rate their current perceived stress level from 1 (no stress) to 10 (extreme stress).
|
Baseline (pre-intervention) and after the 21-day intervention period
|
|
Change in daily stress
Prazo: Baseline(pre-intervention) and after the 21-day intervention period
|
Daily stress is measured using a 26-item self-report scale assessing stress experienced in everyday domains such as parents, school, academics, peer relationships, appearance, and finances, rated on a 5-point Likert scale.
|
Baseline(pre-intervention) and after the 21-day intervention period
|
|
Change in alexithymia
Prazo: Baseline (pre-intervention) and after the 21-day intervention period
|
Difficulty identifying and describing one's own emotions is measured using the Korean version of the 20-item Toronto Alexithymia Scale (TAS-20K), rated on a 5-point Likert scale.
|
Baseline (pre-intervention) and after the 21-day intervention period
|
|
Change in executive function difficulties (self-report)
Prazo: Baseline (pre-intervention) and after the 21-day intervention period
|
Self-reported executive function difficulties are measured using the Brief Self-Report Questionnaire of Executive Function Difficulty for children and adolescents (40 items), rated on a 3-point Likert scale.
|
Baseline (pre-intervention) and after the 21-day intervention period
|
|
Change in peer relationship quality
Prazo: Baseline (pre-intervention) and after the 21-day intervention period
|
The quality of peer relationships is measured using a 13-item self-report scale rated on a 4-point Likert scale, including items reflecting conflict and negative peer interactions.
|
Baseline (pre-intervention) and after the 21-day intervention period
|
|
Change in problem behaviors (CBCL 6-18, parent report)
Prazo: Baseline (pre-intervention) and after the 21-day intervention period
|
Problem behaviors are assessed using the Child Behavior Checklist for Ages 6-18 (CBCL 6-18), completed by a parent or primary caregiver.
It includes internalizing problems (e.g., anxiety, depression, somatic complaints) and externalizing problems (e.g., rule-breaking, aggressive behavior).
|
Baseline (pre-intervention) and after the 21-day intervention period
|
|
Change in ADHD symptoms (ARS, parent report)
Prazo: Baseline (pre-intervention) and after the 21-day intervention period
|
Attention-deficit/hyperactivity symptoms are assessed using the ADHD Rating Scale (ARS), an 18-item parent-report questionnaire comprising inattention and hyperactivity/impulsivity subscales.
|
Baseline (pre-intervention) and after the 21-day intervention period
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Investigadores
- Investigador principal: Hyunjoo Song, PhD, Seoul Women's University
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Estimado)
10 de julho de 2026
Conclusão Primária (Estimado)
28 de fevereiro de 2027
Conclusão do estudo (Estimado)
30 de abril de 2027
Datas de inscrição no estudo
Enviado pela primeira vez
2 de julho de 2026
Enviado pela primeira vez que atendeu aos critérios de CQ
8 de julho de 2026
Primeira postagem (Real)
14 de julho de 2026
Atualizações de registro de estudo
Última Atualização Postada (Real)
14 de julho de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
8 de julho de 2026
Última verificação
1 de julho de 2026
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- SWU-2605-004
- RS-2022-KH126068 (Número de outro subsídio/financiamento: Korea Health Industry Development Institute (KHIDI), Ministry of Health & Welfare, Republic of Korea)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
NÃO
Descrição do plano IPD
Individual participant data will not be shared with other researchers, as participants and their legal guardians were informed during the informed consent process that collected data would not be provided to third parties.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .